The DRUG Access Protocol: access inequality and European harmonisation

Tobias B. Polak; David G.J. Cucchi; Joost van Rosmalen; Carin A. Uyl-de Groot

doi:10.1016/S1470-2045(22)00098-5

The DRUG Access Protocol: access inequality and European harmonisation

Tobias B. Polak^*, David G.J. Cucchi, Joost van Rosmalen, Carin A. Uyl-de Groot

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

3 Citations (Scopus)

39 Downloads (Pure)

Original language	English
Pages (from-to)	e202
Journal	The Lancet Oncology
Volume	23
Issue number	5
DOIs	https://doi.org/10.1016/S1470-2045(22)00098-5
Publication status	Published - 1 May 2022

Bibliographical note

Funding Information:
TBP works part-time for expanded access service provider myTomorrows, in which he holds stock and stock options (<0·01%); he is contractually free to publish, and the service provider is not involved in any of his past or ongoing research, nor this Correspondence. DGJC received payments for lectures for Takeda, outside the submitted work. CAU-dG has received unrestricted grants from Boehringer Ingelheim, Astellas, Celgene, Sanofi, Janssen-Cilag, Bayer, Amgen, Genzyme, Merck, Glycostem Therapeutics, AstraZeneca, Roche, and Merck. CAU-dG, JvR, and TBP work under a Dutch government grant from HealthHolland. In this grant, they specifically research legal, ethical, policy, and statistical issues of evidence generation in compassionate use programmes (EMCLSH20012). HealthHolland is a funding vehicle for the Dutch Ministry of Economic Affairs and Climate Policy that addresses the Dutch Life Sciences & Health sector.

Access to Document

10.1016/S1470-2045(22)00098-5Licence: Unspecified

The DRUG AccessFinal published version, 39.6 KBLicence: Article 25fa Dutch Copyright Act

Cite this

@article{f8619bc9f79645e095a9356bb6783c9a,

title = "The DRUG Access Protocol: access inequality and European harmonisation",

author = "Polak, {Tobias B.} and Cucchi, {David G.J.} and {van Rosmalen}, Joost and {Uyl-de Groot}, {Carin A.}",

note = "Funding Information: TBP works part-time for expanded access service provider myTomorrows, in which he holds stock and stock options (<0·01%); he is contractually free to publish, and the service provider is not involved in any of his past or ongoing research, nor this Correspondence. DGJC received payments for lectures for Takeda, outside the submitted work. CAU-dG has received unrestricted grants from Boehringer Ingelheim, Astellas, Celgene, Sanofi, Janssen-Cilag, Bayer, Amgen, Genzyme, Merck, Glycostem Therapeutics, AstraZeneca, Roche, and Merck. CAU-dG, JvR, and TBP work under a Dutch government grant from HealthHolland. In this grant, they specifically research legal, ethical, policy, and statistical issues of evidence generation in compassionate use programmes (EMCLSH20012). HealthHolland is a funding vehicle for the Dutch Ministry of Economic Affairs and Climate Policy that addresses the Dutch Life Sciences & Health sector.",

year = "2022",

month = may,

day = "1",

doi = "10.1016/S1470-2045(22)00098-5",

language = "English",

volume = "23",

pages = "e202",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "5",

}

TY - JOUR

T1 - The DRUG Access Protocol

T2 - access inequality and European harmonisation

AU - Polak, Tobias B.

AU - Cucchi, David G.J.

AU - van Rosmalen, Joost

AU - Uyl-de Groot, Carin A.

N1 - Funding Information: TBP works part-time for expanded access service provider myTomorrows, in which he holds stock and stock options (<0·01%); he is contractually free to publish, and the service provider is not involved in any of his past or ongoing research, nor this Correspondence. DGJC received payments for lectures for Takeda, outside the submitted work. CAU-dG has received unrestricted grants from Boehringer Ingelheim, Astellas, Celgene, Sanofi, Janssen-Cilag, Bayer, Amgen, Genzyme, Merck, Glycostem Therapeutics, AstraZeneca, Roche, and Merck. CAU-dG, JvR, and TBP work under a Dutch government grant from HealthHolland. In this grant, they specifically research legal, ethical, policy, and statistical issues of evidence generation in compassionate use programmes (EMCLSH20012). HealthHolland is a funding vehicle for the Dutch Ministry of Economic Affairs and Climate Policy that addresses the Dutch Life Sciences & Health sector.

PY - 2022/5/1

Y1 - 2022/5/1

UR - http://www.scopus.com/inward/record.url?scp=85129096844&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(22)00098-5

DO - 10.1016/S1470-2045(22)00098-5

M3 - Comment/Letter to the editor

C2 - 35489346

AN - SCOPUS:85129096844

SN - 1470-2045

VL - 23

SP - e202

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 5

ER -

The DRUG Access Protocol: access inequality and European harmonisation

Bibliographical note

Access to Document

Other files and links

Cite this